Scientific platform for fractional-order population pharmacokinetics.
FractaLPK is developed within the Population Analysis Unit of F.A.T. Laboratories, a spinoff of the National and Kapodistrian University of Athens (NKUA). The platform focuses on a specific niche that classical pharmacometric tools cover poorly: detecting and quantifying anomalous diffusion in pharmacokinetic data.
What makes the combination unique is the pairing of two complementary ideas. On the absorption side, F.A.T. Laboratories’ PBFTPK (Physiologically Based Finite-Time PK) models handle finite-time absorption without the artefacts that classical first-order models introduce when absorption is incomplete or non-exponential. On the disposition side, FractaLPK adds fractional-order kinetics to capture subdiffusive distribution in tissues where classical compartmental models attribute the signal to residual error.
Together they cover the full oral PK pipeline — from finite-time absorption to subdiffusive disposition — in a way that no single commercial tool currently offers.
Background in applied mathematics, fractional calculus, and pharmacometrics.
Developer of the FractaLPK engine. Speaker at the F.A.T. Laboratories Dubrovnik Seminar 2026.
F.A.T. Laboratories (fat-laboratories.com) is a spinoff of the National and Kapodistrian University of Athens (NKUA), Greece, established in October 2025. The company develops model-informed approaches for drug and generics development based on the Finite Absorption Time (F.A.T.) concept.
FractaLPK extends F.A.T.’s PBFTPK structural models with fractional-order disposition kinetics for analyses where anomalous diffusion is observed in drug absorption and distribution.
CEO: Emeritus Prof. Panos Macheras, originator of the Finite Absorption Time concept.